A novel inducible von Willebrand Factor Cre recombinase mouse strain to study microvascular endothelial cell-specific biological processes in vivo
Vascul Pharmacol. 2024 Mar 28:107369. doi: 10.1016/j.vph.2024.107369. Online ahead of print.ABSTRACTMouse models are invaluable to understanding fundamental mechanisms in vascular biology during development, in health and different disease states. Several constitutive or inducible models that selectively knockout or knock in genes in vascular endothelial cells exist; however, functional and phenotypic differences exist between microvascular and macrovascular endothelial cells in different organs. In order to study microvascular endothelial cell-specific biological processes, we developed a Tamoxifen-inducible von Willebran...
Source: Vascular Pharmacology - March 30, 2024 Category: Drugs & Pharmacology Authors: Dinesh Yadav Jeremy A Conner Yimin Wang Thomas L Saunders Eroboghene E Ubogu Source Type: research
Elucidating the crosstalk between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in the pathogenesis of atherosclerosis
Vascul Pharmacol. 2024 Mar 26;155:107368. doi: 10.1016/j.vph.2024.107368. Online ahead of print.ABSTRACTAtherosclerosis, a chronic systemic inflammatory condition, is implicated in most cardiovascular ischemic events. The pathophysiology of atherosclerosis involves various cell types and associated processes, including endothelial cell activation, monocyte recruitment, smooth muscle cell migration, involvement of macrophages and foam cells, and instability of the extracellular matrix. The process of endothelial-to-mesenchymal transition (EndoMT) has recently emerged as a pivotal process in mediating vascular inflammation a...
Source: Vascular Pharmacology - March 28, 2024 Category: Drugs & Pharmacology Authors: Bandana Singh Kui Cui Shahram Eisa-Beygi Bo Zhu Douglas B Cowan Jinjun Shi Da-Zhi Wang Zhenguo Liu Joyce Bischoff Hong Chen Source Type: research
Elucidating the crosstalk between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in the pathogenesis of atherosclerosis
Vascul Pharmacol. 2024 Mar 26;155:107368. doi: 10.1016/j.vph.2024.107368. Online ahead of print.ABSTRACTAtherosclerosis, a chronic systemic inflammatory condition, is implicated in most cardiovascular ischemic events. The pathophysiology of atherosclerosis involves various cell types and associated processes, including endothelial cell activation, monocyte recruitment, smooth muscle cell migration, involvement of macrophages and foam cells, and instability of the extracellular matrix. The process of endothelial-to-mesenchymal transition (EndoMT) has recently emerged as a pivotal process in mediating vascular inflammation a...
Source: Vascular Pharmacology - March 28, 2024 Category: Drugs & Pharmacology Authors: Bandana Singh Kui Cui Shahram Eisa-Beygi Bo Zhu Douglas B Cowan Jinjun Shi Da-Zhi Wang Zhenguo Liu Joyce Bischoff Hong Chen Source Type: research
Elucidating the crosstalk between endothelial-to-mesenchymal transition (EndoMT) and endothelial autophagy in the pathogenesis of atherosclerosis
Vascul Pharmacol. 2024 Mar 26:107368. doi: 10.1016/j.vph.2024.107368. Online ahead of print.ABSTRACTAtherosclerosis, a chronic systemic inflammatory condition, is implicated in most cardiovascular ischemic events. The pathophysiology of atherosclerosis involves various cell types and associated processes, including endothelial cell activation, monocyte recruitment, smooth muscle cell migration, involvement of macrophages and foam cells, and instability of the extracellular matrix. The process of endothelial-to-mesenchymal transition (EndoMT) has recently emerged as a pivotal process in mediating vascular inflammation assoc...
Source: Vascular Pharmacology - March 28, 2024 Category: Drugs & Pharmacology Authors: Bandana Singh Kui Cui Shahram Eisa-Beygi Bo Zhu Douglas B Cowan Jinjun Shi Da-Zhi Wang Zhenguo Liu Joyce Bishoff Hong Chen Source Type: research
PCI versus CABG in coronary artery disease
Vascul Pharmacol. 2024 Mar 18:107367. doi: 10.1016/j.vph.2024.107367. Online ahead of print.ABSTRACTThe evidence basis for percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in coronary artery disease (CAD) has become more firmly established over the last decade in view of new evidence from several large, randomized trials and propensity-matched registries. In comparison to PCI, CABG offers substantial survival benefits and significant reductions in myocardial infarction and need for repeat revascularization in multivessel disease in patients with intermediate and high severity disease, whe...
Source: Vascular Pharmacology - March 20, 2024 Category: Drugs & Pharmacology Authors: David P Taggart Source Type: research
PCI versus CABG in coronary artery disease
Vascul Pharmacol. 2024 Mar 18:107367. doi: 10.1016/j.vph.2024.107367. Online ahead of print.ABSTRACTThe evidence basis for percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in coronary artery disease (CAD) has become more firmly established over the last decade in view of new evidence from several large, randomized trials and propensity-matched registries. In comparison to PCI, CABG offers substantial survival benefits and significant reductions in myocardial infarction and need for repeat revascularization in multivessel disease in patients with intermediate and high severity disease, whe...
Source: Vascular Pharmacology - March 20, 2024 Category: Drugs & Pharmacology Authors: David P Taggart Source Type: research
PCI versus CABG in coronary artery disease
Vascul Pharmacol. 2024 Mar 18:107367. doi: 10.1016/j.vph.2024.107367. Online ahead of print.ABSTRACTThe evidence basis for percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in coronary artery disease (CAD) has become more firmly established over the last decade in view of new evidence from several large, randomized trials and propensity-matched registries. In comparison to PCI, CABG offers substantial survival benefits and significant reductions in myocardial infarction and need for repeat revascularization in multivessel disease in patients with intermediate and high severity disease, whe...
Source: Vascular Pharmacology - March 20, 2024 Category: Drugs & Pharmacology Authors: David P Taggart Source Type: research
PCI versus CABG in coronary artery disease
Vascul Pharmacol. 2024 Mar 18:107367. doi: 10.1016/j.vph.2024.107367. Online ahead of print.ABSTRACTThe evidence basis for percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in coronary artery disease (CAD) has become more firmly established over the last decade in view of new evidence from several large, randomized trials and propensity-matched registries. In comparison to PCI, CABG offers substantial survival benefits and significant reductions in myocardial infarction and need for repeat revascularization in multivessel disease in patients with intermediate and high severity disease, whe...
Source: Vascular Pharmacology - March 20, 2024 Category: Drugs & Pharmacology Authors: David P Taggart Source Type: research
PCI versus CABG in coronary artery disease
Vascul Pharmacol. 2024 Mar 18:107367. doi: 10.1016/j.vph.2024.107367. Online ahead of print.ABSTRACTThe evidence basis for percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in coronary artery disease (CAD) has become more firmly established over the last decade in view of new evidence from several large, randomized trials and propensity-matched registries. In comparison to PCI, CABG offers substantial survival benefits and significant reductions in myocardial infarction and need for repeat revascularization in multivessel disease in patients with intermediate and high severity disease, whe...
Source: Vascular Pharmacology - March 20, 2024 Category: Drugs & Pharmacology Authors: David P Taggart Source Type: research
PCI versus CABG in coronary artery disease
Vascul Pharmacol. 2024 Mar 18:107367. doi: 10.1016/j.vph.2024.107367. Online ahead of print.ABSTRACTThe evidence basis for percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in coronary artery disease (CAD) has become more firmly established over the last decade in view of new evidence from several large, randomized trials and propensity-matched registries. In comparison to PCI, CABG offers substantial survival benefits and significant reductions in myocardial infarction and need for repeat revascularization in multivessel disease in patients with intermediate and high severity disease, whe...
Source: Vascular Pharmacology - March 20, 2024 Category: Drugs & Pharmacology Authors: David P Taggart Source Type: research
Performance of drug-coated balloons in coronary and below-the-knee arteries: Anatomical, physiological and pathological considerations
Vascul Pharmacol. 2024 Mar 11;155:107366. doi: 10.1016/j.vph.2024.107366. Online ahead of print.ABSTRACTBelow-the-knee (infrapopliteal) atherosclerotic disease, which presents as chronic limb-threatening ischemia (CLTI) in nearly 50% of patients, represents a treatment challenge when it comes to the endovascular intervention arm of management. Due to reduced tissue perfusion, patients usually experience pain at rest and atrophic changes correlated to the extent of the compromised perfusion. Unfortunately, the prognosis remains unsatisfactory with 30% of patients requiring major amputation and a mortality rate of 25% within...
Source: Vascular Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Authors: Rafic Ramses Simon Kennedy Richard Good Keith G Oldroyd Sean Mcginty Source Type: research
Performance of drug-coated balloons in coronary and below-the-knee arteries: Anatomical, physiological and pathological considerations
Vascul Pharmacol. 2024 Mar 11:107366. doi: 10.1016/j.vph.2024.107366. Online ahead of print.ABSTRACTBelow-the-knee (infrapopliteal) atherosclerotic disease, which presents as chronic limb-threatening ischemia (CLTI) in nearly 50% of patients, represents a treatment challenge when it comes to the endovascular intervention arm of management. Due to reduced tissue perfusion, patients usually experience pain at rest and atrophic changes correlated to the extent of the compromised perfusion. Unfortunately, the prognosis remains unsatisfactory with 30% of patients requiring major amputation and a mortality rate of 25% within 1 y...
Source: Vascular Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Authors: Rafic Ramses Simon Kennedy Richard Good Keith G Oldroyd Sean Mcginty Source Type: research
Performance of drug-coated balloons in coronary and below-the-knee arteries: Anatomical, physiological and pathological considerations
Vascul Pharmacol. 2024 Mar 11:107366. doi: 10.1016/j.vph.2024.107366. Online ahead of print.ABSTRACTBelow-the-knee (infrapopliteal) atherosclerotic disease, which presents as chronic limb-threatening ischemia (CLTI) in nearly 50% of patients, represents a treatment challenge when it comes to the endovascular intervention arm of management. Due to reduced tissue perfusion, patients usually experience pain at rest and atrophic changes correlated to the extent of the compromised perfusion. Unfortunately, the prognosis remains unsatisfactory with 30% of patients requiring major amputation and a mortality rate of 25% within 1 y...
Source: Vascular Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Authors: Rafic Ramses Simon Kennedy Richard Good Keith G Oldroyd Sean Mcginty Source Type: research
Performance of drug-coated balloons in coronary and below-the-knee arteries: Anatomical, physiological and pathological considerations
Vascul Pharmacol. 2024 Mar 11:107366. doi: 10.1016/j.vph.2024.107366. Online ahead of print.ABSTRACTBelow-the-knee (infrapopliteal) atherosclerotic disease, which presents as chronic limb-threatening ischemia (CLTI) in nearly 50% of patients, represents a treatment challenge when it comes to the endovascular intervention arm of management. Due to reduced tissue perfusion, patients usually experience pain at rest and atrophic changes correlated to the extent of the compromised perfusion. Unfortunately, the prognosis remains unsatisfactory with 30% of patients requiring major amputation and a mortality rate of 25% within 1 y...
Source: Vascular Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Authors: Rafic Ramses Simon Kennedy Richard Good Keith G Oldroyd Sean Mcginty Source Type: research
Performance of drug-coated balloons in coronary and below-the-knee arteries: Anatomical, physiological and pathological considerations
Vascul Pharmacol. 2024 Mar 11:107366. doi: 10.1016/j.vph.2024.107366. Online ahead of print.ABSTRACTBelow-the-knee (infrapopliteal) atherosclerotic disease, which presents as chronic limb-threatening ischemia (CLTI) in nearly 50% of patients, represents a treatment challenge when it comes to the endovascular intervention arm of management. Due to reduced tissue perfusion, patients usually experience pain at rest and atrophic changes correlated to the extent of the compromised perfusion. Unfortunately, the prognosis remains unsatisfactory with 30% of patients requiring major amputation and a mortality rate of 25% within 1 y...
Source: Vascular Pharmacology - March 13, 2024 Category: Drugs & Pharmacology Authors: Rafic Ramses Simon Kennedy Richard Good Keith G Oldroyd Sean Mcginty Source Type: research
